Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Aurobindo Pharma Ltd. (ARBN)
Aurobindo Pharma Ltd. stock price live, this page displays NSE ARBN stock exchange data. View the ARBN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Aurobindo Pharma Ltd. real time stock price chart below.
What Is the Aurobindo Pharma Ltd. Stock Price Today?
The Aurobindo Pharma Ltd. stock price today is 1,706.90.
What Is the Stock Symbol for Aurobindo Pharma Ltd.?
The stock symbol for Aurobindo Pharma Ltd. is "ARBN."
What Stock Exchange Does Aurobindo Pharma Ltd. Trade On?
Aurobindo Pharma Ltd. is listed and trades on the NSE stock exchange.
Is Aurobindo Pharma Ltd. a Good Stock to Buy?
Determining whether Aurobindo Pharma Ltd.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARBN quote. (ISIN: INE406A01037)
What Is the Aurobindo Pharma Ltd. Stock Price Today?
The Aurobindo Pharma Ltd. stock price today is 1,706.90.
What Is the Stock Symbol for Aurobindo Pharma Ltd.?
The stock symbol for Aurobindo Pharma Ltd. is "ARBN."
What Stock Exchange Does Aurobindo Pharma Ltd. Trade On?
Aurobindo Pharma Ltd. is listed and trades on the NSE stock exchange.
Is Aurobindo Pharma Ltd. a Good Stock to Buy?
Determining whether Aurobindo Pharma Ltd.—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ARBN quote. (ISIN: INE406A01037)
1,706.90
+13.90(+0.82%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,681.00
1,715.00
52 wk Range
1,080.10
1,740.00
AUROPHARMA is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1,681.001,715.00
52 wk Range
1,080.101,740.00
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
AUROPHARMA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
1,736.78
Upside
+1.75%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
- Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Aurobindo Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Aurobindo Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Aurobindo Pharma receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
18 Buy
5 Hold
4 Sell
Ratings:
27 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 1,736.78
(+1.75% Upside)
Aurobindo Pharma Ltd. Earnings Call Summary for Q1/2027
- Q1 FY2027 revenue rose 16% YoY to INR 9,150 crore; EBITDA margin at 21% with full-year guidance reaffirmed above INR 8,000 crore.
- Gross margin improved to 60.4% from 58.8%; company shifting from investment phase to monetization with better returns expected.
- Growth markets surged 38% to INR 1,063 crore; Europe up 11% in constant currency; U.S. business grew 8.1% to INR 3,770 crore.
- ADVAIR generic launch set for August 2027; three U.S. biosimilar filings expected within one quarter; TheraNym revenue begins 2028.
- Lannett acquisition running at 40% capacity; management targets $150-200M TheraNym revenue by 2032 with 35-50% EBITDA margins.
Last Updated: 2026-08-06, 12:30 a/m
Read Full TranscriptEarnings
Latest Release
Aug 04, 2026
EPS / Forecast
17.86 / 17.33
Revenue / Forecast
91.5B / 90.3B
Compare AUROPHARMA to Peers and Sector
Metrics to compare | AUROPHARMA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAUROPHARMAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 26.2x | 30.5x | −0.3x | |
PEG Ratio | 2.70 | 0.23 | 0.00 | |
Price/Book | 2.6x | 3.1x | 2.6x | |
Price / LTM Sales | 2.8x | 3.4x | 3.0x | |
Upside (Analyst Target) | 2.6% | 15.3% | 59.8% | |
Fair Value Upside | Unlock | 5.7% | 7.1% | Unlock |
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Aurobindo Pharma (AUROPHARMA) Stock Price Today?
The Aurobindo Pharma stock price today is 1,706.90 INR.
What Stock Exchange Does Aurobindo Pharma Trade On?
Aurobindo Pharma is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Aurobindo Pharma?
The stock symbol for Aurobindo Pharma is "AUROPHARMA."
What Is the Aurobindo Pharma Market Cap?
As of today, Aurobindo Pharma market cap is 982.11B INR.
What Is Aurobindo Pharma's Earnings Per Share (TTM)?
The Aurobindo Pharma EPS (TTM) is 63.99.
When Is the Next Aurobindo Pharma Earnings Date?
Aurobindo Pharma will release its next earnings report on Nov 14, 2026.
From a Technical Analysis Perspective, Is AUROPHARMA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Aurobindo Pharma Stock Split?
Aurobindo Pharma has split 3 times.
How Many Employees Does Aurobindo Pharma Have?
Aurobindo Pharma has 29209 employees.
What is the current trading status of Aurobindo Pharma (AUROPHARMA)?
As of Oct 12, 2026, Aurobindo Pharma (AUROPHARMA) is trading at a price of 1,706.90 INR, with a previous close of 1,706.90 INR. The stock has fluctuated within a day range of 1,681.00 INR to 1,715.00 INR, while its 52-week range spans from 1,080.10 INR to 1,740.00 INR.
What Is Aurobindo Pharma (AUROPHARMA) Price Target According to Analysts?
The average 12-month price target for Aurobindo Pharma is 1,736.78 INR, with a high estimate of 2000 INR and a low estimate of 1270 INR. 18 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Buy. The stock has an +1.75% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.